Are CAR-T therapies for solid tumors ready for clinical translation?

Why haven't CAR-T cells worked in solid tumors yet?

The same therapy that cures blood cancers fails against solid tumors because solid cancers build a physical and chemical fortress. CAR-T cells must first travel through the bloodstream and squeeze into the tumor mass (trafficking), then survive inside a hostile microenvironment that actively suppresses immune cells [2][3]. Multiple studies converge on this: the tumor microenvironment (TME) is described as 'immunosuppressive' in nearly every review here [2][4][5][7][9][10]. For example, a 2024 review in Cellular & Molecular Immunology notes that limited tumor trafficking and infiltration are key obstacles [2], while a 2025 review in Cancer Cell emphasizes the TME's role in limiting effectiveness [4].

A second major barrier is antigen heterogeneity — not all cancer cells in a solid tumor display the same target protein. This means a CAR-T cell designed to recognize one antigen will miss many tumor cells, allowing the cancer to regrow [4][5][11]. A 2022 study in The Journal of Clinical Investigation highlights this problem in neuroblastoma and describes a bicistronic CAR-T cell that targets multiple antigens to overcome it [11]. A third challenge is identifying safe targets: many antigens found on solid tumors are also present on healthy tissues, raising the risk of 'on-target, off-tumor' toxicity, where CAR-T cells attack normal organs [3][10].

Is there any evidence that CAR-T cells can work against solid tumors?

Yes, but the evidence is early and mostly from small trials or animal models — not yet from large, definitive human studies. The most concrete clinical data comes from a 2023 study in Science Advances, which tested mesothelin-targeting CAR-T cells delivered in a fibrin glue carrier after incomplete surgery in mice. This local delivery cleared residual cancer cells and significantly prolonged survival compared to surgery alone or surgery plus CAR-T cells without the glue [6]. The same study reports that a clinical trial in patients with locally advanced breast cancer is now planned [6].

In human trials, early results for GD2-targeted CAR-T cells in pediatric neuroblastoma and HER2-targeted CAR-T cells in other solid tumors have been 'encouraging' but need validation on a larger scale [7]. A 2024 JAMA review notes that two T-lymphocyte-based therapies (not CAR-T, but related) have gained FDA approval for melanoma and synovial cell sarcoma, and that CAR-T-like responses have been seen in pediatric neuroblastoma and HPV-associated cancers [1]. However, the same review explicitly states that no CAR-T therapy is FDA-approved for solid tumors [1]. A 2025 review in Cancers confirms that despite accelerating innovation and patent activity, no CAR-T product has been approved for solid tumors [9].

What are researchers doing to make CAR-T cells work for solid tumors?

Researchers are engineering multiple upgrades to CAR-T cells to overcome the barriers. One major approach is 'armored' CAR-T cells that secrete molecules to resist the suppressive tumor environment or that combine with immune checkpoint inhibitors (like PD-1 blockers) to keep the T cells active [4][5][9]. A 2025 review in Cancer Cell highlights combining CAR-T with checkpoint inhibitors as a key strategy to overcome TME limitations [4].

Another strategy is dual-targeting: engineering CAR-T cells to recognize two or more tumor antigens at once, reducing the chance that antigen heterogeneity allows escape [5][11]. The bicistronic CAR-T cells described in a 2022 JCI study target multiple neuroblastoma antigens simultaneously [11]. A third innovation is local delivery: the fibrin glue method from the 2023 Science Advances study delivered CAR-T cells directly to the surgical site, improving efficacy and reducing toxicity [6]. Finally, a 2025 paper in the Journal for Immunotherapy of Cancer introduces a quantitative systems pharmacology (QSP) model that uses computer simulations to predict patient responses and optimize dosing for solid tumor CAR-T therapies, potentially accelerating clinical trial design [8]. These strategies are largely still in preclinical or early clinical testing, but they represent a clear path forward.

About These Sources

This answer is built on 11 peer-reviewed studies — published from 2022 to 2026, 7 from 2024 or later, 9 in Q1 journals, collectively cited 805 times — selected as the most relevant from 13 studies that passed quality screening, drawn from 60 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions